Redundancy and robustness versus division of labour and specialization in innate immunity

Seminars in Immunology

Volumn 36, Issue , 2018, Pages 28-30

  Mantovani, Alberto ^a,b,c  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^b HUMANITAS UNIVERSITY   (Italy)

^c QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Chemokines; Cytokines; Inflammation; Innate immunity; Macrophages; Neutrophils; Phagocytes; Tissue repair

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; PENTRAXIN 3; CHEMOKINE; CYTOKINE; PATTERN RECOGNITION RECEPTOR;

ADAPTIVE IMMUNITY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENETIC VARIATION; HUMAN; IMMUNOREGULATION; INNATE IMMUNITY; NONHUMAN; PHAGOCYTE; REVIEW; ANIMAL; CELL MOTION; EVOLUTION; GENETIC POLYMORPHISM; IMMUNOLOGY; INFLAMMATION;

ADAPTIVE IMMUNITY; ANIMALS; BIOLOGICAL EVOLUTION; CELL MOVEMENT; CHEMOKINES; CYTOKINES; HUMANS; IMMUNITY, INNATE; INFLAMMATION; PHAGOCYTES; POLYMORPHISM, GENETIC; RECEPTORS, PATTERN RECOGNITION;

EID: 85038832877     PISSN: 10445323     EISSN: 10963618     Source Type: Journal    
DOI: 10.1016/j.smim.2017.12.006     Document Type: Review

References (23)

1. Dinarello, C.A., Simon, A., van der Meer, J.W., Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat. Rev. Drug Discov. 11 (2012), 633–652.
2. Dinarello, C.A., Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117 (2011), 3720–3732.
3. Muzio, M., Ni, J., Feng, P., Dixit, V.M.I.R.A.K., (Pelle) family member IRAK-2 and MyD88 as proximal mediators of IL-1 signaling. Science 278 (1997), 1612–1615.
4. Garlanda, C., Dinarello, C.A., Mantovani, A., The interleukin-1 family: back to the future. Immunity 39 (2013), 1003–1018.
5. Mantovani, A., Sica, A., Sozzani, S., Allavena, P., Vecchi, A., Locati, M., The chemokine system in diverse forms of macrophage activation and polarization. Trends Immunol. 25 (2004), 677–686.
6. Mantovani, A., Bonecchi, R., Locati, M., Tuning inflammation and immunity by chemokine sequestration: decoys and more. Nat. Rev. Immunol. 6 (2006), 907–918.
7. Griffith, J.W., Sokol, C.L., Luster, A.D., Chemokines and chemokine receptors: positioning cells for host defense and immunity. Annu. Rev. Immunol. 32 (2014), 659–702.
8. Murphy, P.M., Chemokines and the molecular basis of cancer metastasis. N. Engl. J. Med. 345 (2001), 833–835.
9. Zlotnik, A., Yoshie, O., The chemokine superfamily revisited. Immunity 36 (2012), 705–716.
10. Mantovani, A., The chemokine system: redundancy for robust outputs. Immunol. Today 20 (1999), 254–257.
11. Truchetet, M.E., Pradeau, T., Re-thinking our understanding of immunity: robustness in the tissue reconstruction system. Semin. Immunol., 2018 (in press).
12. Dinarello, C., Arend, W., Sims, J., Smith, D., Blumberg, H., O'Neill, L., et al. IL-1 family nomenclature. Nat. Immunol., 11, 2010, 973.
13. Dinarello, C.A., Immunological and inflammatory functions of the interleukin-1 family. Annu. Rev. Immunol. 27 (2009), 519–550.
14. Ridker, P.M., MacFadyen, J.G., Thuren, T., Everett, B.M., Libby, P., Glynn, R.J., Effect of interleukin-1beta inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. Lancet 390 (2017), 1833–1842.
15. Ridker, P.M., Everett, B.M., Thuren, T., MacFadyen, J.G., Chang, W.H., Ballantyne, C., et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N. Engl. J. Med. 377 (2017), 1119–1131.
16. Bottazzi, B., Doni, A., Garlanda, C., Mantovani, A., An integrated view of humoral innate immunity: pentraxins as a paradigm. Annu. Rev. Immunol. 28 (2010), 157–183.
17. Garlanda, C., Bottazzi, B., Bastone, A., Mantovani, A., Pentraxins at the crossroads between innate immunity, inflammation, matrix deposition, and female fertility. Annu. Rev. Immunol. 23 (2005), 337–366.
18. Garlanda, C., Bottazzi, B., Magrini, E., Inforzato, A., Mantovani, A., PTX3, a key component of humoral innate immunity at the interface between defense and tissue remodeling. Physiol. Rev., 2017 (in press).
19. Graham, G.J., Locati, M., Mantovani, A., Rot, A., Thelen, M., The biochemistry and biology of the atypical chemokine receptors. Immunol. Lett. 145 (2012), 30–38.
20. Cardona, A.E., Sasse, M.E., Liu, L., Cardona, S.M., Mizutani, M., Savarin, C., et al. Scavenging roles of chemokine receptors: chemokine receptor deficiency is associated with increased levels of ligand in circulation and tissues. Blood 112 (2008), 256–263.
21. Nagasawa, T., Hirota, S., Tachibana, K., Takakura, N., Nishikawa, S., Kitamura, Y., et al. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature 382 (1996), 635–638.
22. Bachelerie, F., Ben-Baruch, A., Burkhardt, A.M., Combadiere, C., Farber, J.M., Graham, G.J., et al. International Union of Basic and Clinical Pharmacology: [corrected]. LXXXIX. Update on the extended family of chemokine receptors and introducing a new nomenclature for atypical chemokine receptors. Pharmacol. Rev. 66 (2014), 1–79.
23. Duchene, J., Novitzky-Basso, I., Thiriot, A., Casanova-Acebes, M., Bianchini, M., Etheridge, S.L., et al. Atypical chemokine receptor 1 on nucleated erythroid cells regulates hematopoiesis. Nat. Immunol. 18 (2017), 753–761.